@—Õ°–òŠw

 

’˜@‘

 

1)@¼ŒûHŽiFˆã—ÖòŠwm‘æ6”ÅnC–x—¹•½AŠ£Œ«ˆêA‰œ‘ºŸ•FŠÄCCœAì‘“Xo”Å (2014).

 

2)@¼ŒûHŽiFƒVƒiƒŠƒI@Ç—á‰ðÍ\ˆã—Â̌»ê‚Å¡\[‘æ2”Å]CûüŽR–¾‘•ÒWC‹ž“sœAì‘“Xo”Å

    (2014).

 

˜_@•¶

 

1)       “’ŒŽãÄ‘¾A•õŠ_“N–çA”Œˆä—ŒbŽqA“¡ˆä®ŽqAà_“c”ü‹PAŽá—Ñ–¢‹HAâ“Œ‹G•zŽqA‹{¼—ljÀA–àˆä‰À“ÞA’Ò–{‰ë”VA¼ŒûHŽi. ƒAƒ€ƒƒWƒsƒ“ƒxƒVƒ‹Ž_‰–»Ü‚ÆŽ_‰»ƒ}ƒOƒlƒVƒEƒ€»Ü‚Ì“¯ŽžŠÈˆÕŒœ‘÷‚É‚æ‚éŽå–ò—Ê‚Ì•Ï“®. ˆã—ÖòŠw40, 252-257 (2014).

 

2)       Hitoshi Uchiyama, Masayuki Tsujimoto, Tadakazu Shinmoto, Hitomi Ogino, Tomoko Oda, Takuya Yoshida, Taku Furukubo, Satoshi Izumi, Tomoyuki Yamakawa, Hidehisa Tachiki, Tetsuya Minegaki and Kohshi Nishiguchi. Uremic Toxins enhance statin-Induced cytotoxicity in differentiated human rhabdomyosarcoma cells.  Toxins, 6, 2612-2625 (2014).

 

3)       Masayuki Tsujimoto, Sari Sugimoto, Makiko Nagatomo, Taku Furukubo, Satoshi Izumi, Tomoyuki Yamakawa, Tetsuya Minegaki, and Kohshi Nishiguchi. Possibility of decrease in CYP1A2 function in patients with end-stage renal disease.  Therapeutic Apheresis and Dialysis, 18, 174-180 (2014).

 

4)       Kyoko Seki, Yasuo Tsuduki, Takeshi Ioroi, Michiko Yamane, Hiroko Yamauchi, Yukinari Shiraishi, Tadaaki Ogawa, Izumi Nakata, Kohshi Nishiguchi, Teruhisa Matsubayashi, Yoshihide Takakubo, Motohiro Yamamori, Akiko Kuwahara, Noboru Okamura, and Toshiyuki Sakaeda. Serum lactate dehydrogenase  levels as a predictive marker of oxaliplatin-induced hypersensitivity reactions in Japanese patients with advanced colorectal cancer.  Int.J.Med.Sci.11, 641-645 (2014).

 

5)       Tetsuya Minegaki, Akiko Kuwahara, Motohiro Yamamori, Tsutomu Nakamura, Tatsuya Okuno, Ikuya Miki, Hideaki Omatsu, Takao Tamura, Midori Hirai, Takeshi Azuma, Toshiyuki Sakaeda, and Kohshi Nishiguchi. Genetic polymorphisms in SLC23A2 as predictive biomarkers of severe acute toxicities after treatment with a definitive 5-fluorouracil/cisplatin-based chemoradiotherapy in Japanese patients with esophageal squamous cell carcinoma .  Int.J.Med.Sci.11, 321-326(2014).

 

 

 

‰ðàA•ñ‘“™

 

1)      ¼ŒûHŽiFDo you know?|POCT|“ú–{•a‰@–òÜŽt‰ïŽGŽ, 50, 141 (2014).

 

2)@¼ŒûHŽiFDo you know? |Syk‘jŠQ–ò|“ú–{•a‰@–òÜŽt‰ïŽGŽ, 50 , 900 (2014).

 

Šw‰ï”­•\“™

 

@Šw‰ï”­•\

 

1)      ¼–{ŒõŽiA’Ò–{‰ë”VA‹g“c‘ñ–íAZ–{Ø“EA{–{^—ŽqA’†ì’q‰ÁA¬ì‰ÀDA_Œ´Œ’ŒáA’¹‹“Þ‰›A“ü]—TŽqAìãË‘ãA’†’J¹‹IA“¡‰ªt”TA•õŠ_“N–çA¼ŒûHŽiFƒAƒŠƒXƒLƒŒƒ“‚ÌŠÌÁŽ¸‰ß’ö‚É‹y‚Ú‚·—L‹@ƒAƒjƒIƒ“—A‘—ƒ|ƒŠƒyƒvƒ`ƒh1‚a1‚̉e‹¿D“ú–{–òŠw‰ï‘æ134”N‰ï (ŒF–{), 2014.3.

 

2)      “›ˆäFŽ¡A’Ò–{‰ë”VA“àŽRmA“‡“c“Þ‰›”üAV“cʉÀA–Ø‘ºŽé—›A²”Œ’AŒ‹éŠG—ŽqA‹g“c‘ñ–íAŒÃ‹v•Û‘ñA˜aò’qAŽRì’q”VA•õŠ_“N–çA—§–ØG®A¼ŒûHŽiF––Šút•s‘SŠ³ŽÒŒŒ´‚ð’·Šú–\˜I‚µ‚½‰¡–ä‹Ø×–E‚Ì컂Ƃ»‚Ì‹@”\•]‰¿D“ú–{–òŠw‰ï‘æ134”N‰ï (ŒF–{), 2014.3.

 

3)      “àŽRmA’Ò–{‰ë”VA‰¬–ìm–¢A¬“c’qŽqAV–{—BˆêA“‡“c“Þ‰›”üA“›ˆäFŽ¡AV“cʉÀA‹g“c‘ñ–íAŒÃ‹v•Û‘ñA˜aò’qAŽRì’q”VA•õŠ_“N–çA—§–ØG®A¼ŒûHŽiFƒqƒg‰¡–ä‹Øƒ‚ƒfƒ‹×–E‚ð—p‚¢‚½ƒXƒ^ƒ`ƒ“‚É‚æ‚鉡–ä‹ØáŠQ‚Ö‚Ì”A“ÅÇ•¨Ž¿‚ÌŠÖ—^‚Æ‚»‚Ì‘‹­ƒƒJƒjƒYƒ€‚ÌŒŸ“¢D“ú–{–òŠw‰ï‘æ134”N‰ï (ŒF–{), 2014.3.

 

4)      •Ÿ“‡¹DA•õŠ_“N–çA‰F–쇋RA‚—œm”üAX‰ªçqA’ÒžxAŽR–{’mŽuA“n糈¤—œA’Ò–{‰ë”VA¼ŒûHŽiFƒqƒgH“¹Šà×–EŠ”‚Ì‘B‚É‹y‚Ú‚·ƒrƒXƒzƒXƒzƒl[ƒgŒn–ò•¨‚̉e‹¿D“ú–{–òŠw‰ï‘æ134”N‰ï (ŒF–{), 2014.3.

 

5)      ‹g“c‘ñ–íA’Ò–{‰ë”VAZ–{Ø“EA{–{^—ŽqA’†ì’q‰ÁA¼–{ŒõŽiA“ü]—TŽqAìãË‘ãA’†’J¹‹IA“¡‰ªt”TA•õŠ_“N–çA¼ŒûHŽiFÁ‰»ŠÇƒ‚ƒfƒ‹Caco-2×–E‚É‚¨‚¯‚é”AŽ_‚ƃCƒ“ƒhƒLƒVƒ‹—°Ž_‚Ì‘ŠŒÝì—p‚ÉŠÖ‚·‚é“®‘ÔŠw“IŒ¤‹†Dˆã—ÖòŠwƒtƒH[ƒ‰ƒ€2014^‘æ22‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@[ƒ}ƒV[ƒVƒ“ƒ|ƒWƒEƒ€ (“Œ‹ž), 2014.6.

 

6)      Žá—Ñ–¢‹HA•õŠ_“N–çAà_“c”ü‹PAM‘¾Œb—ØA’†“‡DA•s”j“OAóˆä–ƒ—C—¢A‘弌‹ŠóA“¡–{”ü¹‹IA’Ò–{‰ë”VA¼ŒûHŽiFŠÈˆÕŒœ‘÷–@‚É‚¨‚¯‚éƒWƒqƒhƒƒsƒŠƒWƒ“ŒnCahR–ò‚ÆŽ_‰»ƒ}ƒOƒlƒVƒEƒ€ù‚Ì”z‡•Ï‰»Dˆã—ÖòŠwƒtƒH[ƒ‰ƒ€2014^‘æ22‰ñƒNƒŠƒjƒJƒ‹ƒtƒ@[ƒ}ƒV[ƒVƒ“ƒ|ƒWƒEƒ€ (“Œ‹ž), 2014.6.

7)      Masayuki Tsujimoto, Hitoshi Uchiyama, Tadakazu Shinmoto, Hitomi Ogino, Tomoko Oda, Takuya Yoshida, Taku Furukubo, Satoshi Izumi, Tomoyuki Yamakawa, Hedehisa Tachiki, Tetsuya Minegaki, Kohshi Nishiguchi: Effect of uremic toxins on statin-induced cytotoxicity in patients with end-stage renal failure. 2014 Annual Meeting American College of Clinical Pharmacology (Atlanta, GA, USA), 2014.9.

 

8)      –kŽR—zØA’Ò–{‰ë”VAŽ›”öÊA•Ÿ“c’qÆAì’[”ü•äAœA숤AŽR“c—L—¢ŽqA•õŠ_“N–çA¼ŒûHŽiF¶‘Ì“à•K{”÷—ÊŒ³‘f—Ê‚Ì•Ï“®‚ªCYP3A4‹@”\‚É‹y‚Ú‚·‰e‹¿D‘æ24‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (–¼ŒÃ‰®), 2014.9.

 

9)      •õŠ_“N–çAX‰ªçqA•Ÿ“‡¹DA‚—œm”üA‰F–쇋RA’ÒžxAŽR–{’mŽuA“n糈¤—œA’Ò–{‰ë”VA¼ŒûHŽiFƒrƒXƒzƒXƒzƒl[ƒgŒn–ò•¨‚̃qƒgH“¹Šà×–EŠ”‚ɑ΂·‚é×–E“Å«ƒƒJƒjƒYƒ€‚̉ð–¾D‘æ24‰ñ“ú–{ˆã—ÖòŠw‰ï”N‰ï (–¼ŒÃ‰®), 2014.9.

 

10)   ¬o”Ž‹`A’Ò–{‰ë”VAZ–{Ø“EA{–{^—ŽqA’†ì’q‰ÁA¼–{ŒõŽiA¬ì‰ÀDA_Œ´Œ’ŒáA’¹‹“Þ‰›A“ü]—TŽqAìãË‘ãA’†’J¹‹IA“¡‰ªt”TA‹g“c‘ñ–íA•õŠ_“N–çA¼ŒûHŽiFƒVƒNƒƒXƒ|ƒŠƒ“‚É‚æ‚éƒAƒŠƒXƒLƒŒƒ“ÁŽ¸’x‰„‚Ö‚Ì—L‹@ƒAƒjƒIƒ“—A‘—ƒ|ƒŠƒyƒvƒ`ƒh1B1‚ÌŠÖ—^‚ÉŠÖ‚·‚錟“¢D‘æ64‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ï (‹ž“s), 2014.10.

 

11)   Ÿ•”—F—ŒbA’Ò–{‰ë”VA—Ž‡ˆ¤A¬o”Ž‹`A–kðˆŸ–îŽqAZ–{Ø“EA{–{^—ŽqA’†ì’q‰ÁA¼–{ŒõŽiA¬ì‰ÀDA_Œ´Œ’ŒáA’¹‹“Þ‰›AŽu–€‘å‰îAŒÃ‹v•Û‘ñA˜aò’qAŽRì’q”VA•õŠ_“N–çA¼ŒûHŽiFƒCƒŠƒmƒeƒJƒ“Šˆ«‘ãŽÓ•¨SN-38ŠÌŽæ‚èž‚Ý‚É‹y‚Ú‚·”A“ÅÇ•¨Ž¿‹y‚уAƒ‹ƒuƒ~ƒ“‚̉e‹¿D‘æ64‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ï (‹ž“s), 2014.10.

 

12)   “n糈¤—œA•õŠ_“N–çA’ÒžxAŽR–{’mŽuAœö–ع–ëA“¹‰Æ—Y‘¾˜YAŽRªçqA’Ò–{‰ë”VA¼ŒûHŽiF5-FU‘Ï«ƒqƒg“ûŠà×–EŠ”‚ÌŽ÷—§‚Æ‚»‚̃ƒJƒjƒYƒ€‚̉ð–¾D‘æ64‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ï (‹ž“s), 2014.10. —DGƒ|ƒXƒ^[ÜŽóÜ

 

13)   ’I‹´^ŽÀA•õŠ_“N–çA‹{–{Œb•ãAŽR–{ʉÀAr–Ø—IAˆîŠ_Œb–¢A—ÑŠG—¢A’Ò–{‰ë”VA¼ŒûHŽiFH“¹Šà×–EŠ”‚É‚¨‚¯‚éPARP‘jŠQÜ‚Æ×–EáŠQ«RŠàÜ‚Æ‚Ì‘Šæ“I‚È‘B—}§Œø‰ÊD‘æ64‰ñ“ú–{–òŠw‰ï‹ß‹EŽx•”‘‰ïE‘å‰ï (‹ž“s), 2014.10.

 

14)   ¬ì‰ÀDA’Ò–{‰ë”VA‹g“c‘ñ–íA_Œ´Œ’ŒáA’¹‹“Þ‰›A•õŠ_“N–çA¼ŒûHŽiFt”A׊ǃ‚ƒfƒ‹HK-2×–E‚É‚¨‚¯‚éƒCƒ“ƒhƒLƒVƒ‹—°Ž_‚Ì“®‘Ô‚É‹y‚Ú‚·”AŽ_‚̉e‹¿D‘æ8‰ñ“ú–{t‘Ÿ•a–ò•¨—Ö@Šw‰ïŠwpW‰ïE‘‰ï2014 (‘åã), 2014.10. —DG‰‰‘èÜŽóÜ

 

15)   ˆÉ“¡‚Ȃ‚±A’Ò–{‰ë”VA“àŽRmA¬àV«ˆêAX‰º’qŒbAŒÃ‹v•Û‘ñA˜aò’qAŽRì’q”VA—§–ØG®A•õŠ_“N–çA¼ŒûHŽiFƒqƒg‘å’°Šà—R—ˆ×–EŠ”LS180×–E‚ÌRŠàÜŠ´Žó«‚É‹y‚Ú‚·––Šút•s‘SŠ³ŽÒŒŒ´‚̉e‹¿D‘æ35‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ï (¼ŽR), 2014.12.

 

u‰‰“™

 

1)   ’Ò–{‰ë”VF“Á•Êu‰‰u–ò–òŠw˜AŒg‚É‚æ‚éƒGƒrƒfƒ“ƒX‘n»‚ð–ÚŽw‚µ‚Ä`ƒGƒrƒfƒ“ƒX‚È‚«íŽ¯‚Ö‚Ì’§í`v.@‘æ11‰ñPharm. Café (‘åã), 2014.3.

 

2)   ¼ŒûHŽiFƒVƒ“ƒ|ƒWƒEƒ€uƒWƒFƒlƒŠƒbƒNˆã–ò•i‚̻ܕiŽ¿•]‰¿v.@“ú–{•a‰@–òÜŽt‰ï“Œ–kƒuƒƒbƒN‘æ4‰ñŠwp‘å‰ï (å‘ä), 2014.5.

 

3)   ¼ŒûHŽiF‹ž“s–ò‰È‘åŠw‘åŠwà–¾‰ï (–¼ŒÃ‰®), 2014.8.

 

4)@’Ò–{‰ë”VFƒI[ƒKƒiƒCƒU[ Œ“ ‰‰ŽÒ@ƒ[ƒNƒVƒ‡ƒbƒv@–òŠw¶‚Ì‚½‚ß‚ÌŠî‘b‚©‚çŠw‚ÔCKD–ò•¨—Ö@uŽåŽ|à–¾`–òŠw•”‚ÅŠw‚ñ‚¾‚±‚Æ‚ªŽÀ—Õ°‚Å‚Ç‚¤Šˆ‚©‚¹‚é‚Ì‚©H`v. ‘æ8‰ñ“ú–{t‘Ÿ•a–ò•¨—Ö@Šw‰ïŠwpW‰ïE‘‰ï2014 (‘åã), 2014.10.

 

‚»‚Ì‘¼

 

1)@¼ŒûHŽiFŽQ‰Á@•½¬26”N“x–òŠw‹¤—pŽŽŒ±OSCEà–¾‰ï (‹ž“s), 2014.4.

 

2)@¼ŒûHŽiA’Ò–{‰ë”VA•õŠ_“N–ç: ‘ÌŒ±ŽÀKuì‚낤“îpIŽg‚¨‚¤“îpIv. ‹ž“s–ò‰È‘åŠwƒI[ƒvƒ“ƒLƒƒƒ“ƒpƒX (‹ž“s), 2014.8.

 

3)  ‰ªè^”gA’Ò–{‰ë”VA¬o”Ž‹`AŽO‰Y—L‰Ô—¢A•õŠ_“N–çA¼ŒûHŽiFSN-38‚Ì×–E‘B—}§Œø‰Ê‚É‹y‚Ú‚·ƒR[ƒq[ˆ’u‚̉e‹¿D‘æ4‰ñ4‘åŠw˜AŒgŒ¤‹†ƒtƒH[ƒ‰ƒ€ (‹ž“s), 2014.12.